182 results about "Pancreatic tissue" patented technology

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Le^a and Le(y) antibodies that bind to the Lewis antigens.

The method of stimulating a tissue of a subsurface organ is disclosed. The method has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves; and subjecting the tissue to the acoustic shock waves stimulating said tissue wherein the tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. In one embodiment the emitted shock waves are divergent or near planar. In another embodiment the emitted shock waves are convergent having a geometric focal volume of point at a distance of at least X from the source, the method further comprising positioning the tissue at a distance less than the distance X from the source. The subsurface organ is a tissue having cells. The tissue is a part of the incretin system. The subsurface organ is preferably the pancreas of a diabetic or at risk diabetic patient. The treatment stimulates the pancreatic tissue by an analgesic effect on the nerves and a stimulation of the insulin producing islets.

The invention relates to a traditional Chinese medicine, in particular to a traditional Chinese medicine for treating diabetes, which is prepared from 20 traditional Chinese drugs comprising America ginseng, rhizoma anemarrhenae, balsam pear, Chinese yam and the like. The invention is developed on the principle of treating both principal and secondary aspect of disease in Chinese medicine; after diabetes is treated, the efficiency of treatment on the fasting blood-glucose is 30.6-50%, and the efficiency of the treatment on the postprandial blood sugar is 36-61.3%; and especially in the animal experiment, the traditional Chinese medicine can enable the sugar tolerance curve of the hyperglycaemia rabbit in a rabbit tetraoxypyrimidine-model to obviously descend, obviously enhance the sugar tolerance of rabbits and promote rabbits in the hyperglycemia state to excrete insulin, and has certain repair function on pancreatic tissue damage caused by tetraoxypyrimidine. The traditional Chinese medicine can enhance the insulin release for patients with diabetes after treatment, obviously increase the postprandial insulin and obviously improve the symptoms of diabetes. The clinical experiment indicates that the traditional Chinese medicine is safe to take and reliable in curative effect, have no abnormal effect on the functions of the heart, liver and kidney as well as the blood system, and have no other adverse effects and toxic or side effect.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem/progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and/or pancreatic islet cells) are also provided. Methods of using the multipotent cells and/or multipotent cell populations are also provided.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The invention discloses a label-free pancreatic image automatic segmentation system based on adversarial learning, and the system employs an adversarial learning method to search label image data and common image features in label-free image data, and strengthens the personalized image features of the label-free image data, and a pancreas image segmentation model suitable for the label-free pancreas CT image is constructed; a Transform structure is introduced to segment a pancreas CT image, pixel block partition processing is performed on pancreas CT image data, a self-attention mechanism is added to establish a long-connection cross-correlation relation between pixel blocks, a residual structure is used in a multi-stage encoder-decoder structure, multi-scale pancreas target image features can be subjected to weighted interaction, and the segmentation effect on small targets such as pancreatic tissues is obviously improved. According to the method, a reliable segmentation result can be given for label-free pancreas CT image data, the film reading time of a doctor is effectively shortened, the diagnosis and treatment process of pancreas-related diseases is optimized, and the diagnosis and treatment efficiency of the doctor is improved.

Endoscopic approach necrosectomy assist devices and methods of use to collect necrotic pancreatic tissue. One embodiment of the device includes a body, an expandable cap on a distal end of the body, an actuating mechanism for causing the cap to move between a reduced diameter retracted state and an expanded diameter operational state, a tissue collecting band on the cap, and a band actuating mechanism. Another embodiment of the invention includes a handle and a scoop on the handle. The scoop is movable between a reduced diameter retracted state and an expanded diameter operational state. The scoop is formed from a shape memory material and is self biased to the operational state. Blades, rake tips, cutters or abrasive can be included on the scoop.

The invention discloses a novel highly efficient method for preparing a mice pancreatic single cell suspension. The method comprises the steps of selection of mouse pancreas, cold digestion of pancreatin, separation and purification of pancreatic single cells and the like. The key technology of the method is that: the pancreatin is used for invading the pancreatic tissue under conditions of low temperature and low activity, and the pancreatic tissue is dissociated by a short warm digestion so as to obtain the pancreatic single cell suspension with high quantity, high purification, high activity and no adhesion. Compared with the common pancreatic cell separation method, the method of the invention has the characteristics of stable operation, high cell yield, high cell activity and the like, avoids the defect existing in the common pancreatic cell separation method that the pancreatic cells are damaged due to long-time warm incubation of the pancreatin, the DNA released when the cells are died in large quantity is wound so as to cause the cell adhesion and the like, solves the problem of difficult separation and analysis of the pancreatic single cells and lays a foundation for further using the pancreatic cells.

The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (β cells). It therefore regulates the serum levels of this hormone. Furthermore, it restores and maintains the normal concentrations of the blood glucose.

The invention belongs to the technical field of special medicinal food production, and specifically relates to prebiotics-containing formula food for special medicinal use in diabetes and a preparation method thereof. The prebiotics-containing formula food is prepared from the following components in percentage: 15 to 40 percent of yam flour, 11 to 15 percent of whey protein, 10 to 14 percent of resistant dextrin, 8 to 12 percent of walnut powder, 8 to 12 percent of xylitol, 12 to 20 percent of composite peptide powder, 5 to 9 percent of L-arabinose, 5 to 9 percent of inulin, 4 to 8 percent ofxylooliosaccaride powder 95, 0.080 to 0.1 percent of decavitamin, 0.4 to 0.45 percent of composite minerals, 2 to 6 percent of a momordica charantia extract and 1 to 5 percent of a herba gynostemmatis extract. The prebiotics-containing formula food disclosed by the invention not only is capable of effectively reducing blood glucose, but also has the functions of increasing the anti-oxidative stress ability of diabetic mice and reducing the lipotoxicity, and the function of protecting pancreatic tissues can be achieved.

The invention discloses a pressure wave diabetes therapeutic machine which mainly comprises a pressure wave generation device for releasing pressure wave to focus pancreatic tissue through high pressure electric pulse in a liquid medium, wherein the pressure wave generation device is selected from one of an electromagnetic effect pressure wave pulse generation device, a liquid-electric effect pressure wave pulse generation device and a dielectric effect pressure wave pulse generation device. According to the pressure wave diabetes therapeutic machine, a microcirculatory system of the pancreatic tissue is changed through pressure wave, the pancreatic tissue is activated and repaired, and normal secretion of pancreas insulin is improved, therefore, the purpose of treating diabetes is achieved.